Last reviewed · How we verify
NCT04529824
Glucose Risk Assessment in Employer Populations
trial testing Dexcom G6 Continuous Glucose Monitor (CGM) System in Diabetes in 207 participants. Completed in 1 August 2021.
22 July 2019
Quick facts
| Lead sponsor | DexCom, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 207 |
| Start date | 1 April 2019 |
| Primary completion | 22 July 2019 |
| Estimated completion | 1 August 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dexcom G6 Continuous Glucose Monitor (CGM) System
Conditions studied
- Diabetes — all drugs for Diabetes →
- Pre-diabetes — all drugs for Pre-diabetes →
- Glucose Intolerance — all drugs for Glucose Intolerance →
Sponsor
DexCom, Inc.
Who can join
18 and older, any sex, with Diabetes or Pre-diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational study to understand the glucose characteristics of the general population (normal glucose, pre-diabetes, and diabetes). Glucose risk will be measured with laboratory HbA1c and continuous glucose monitor (CGM) derived metrics. Physical activity will also be measured using a Fitbit activity tracker. The study will inform future programs that use CGM and activity tracking to identify people at risk for diabetes in the population.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Including Continuous Glucose Monitoring to Provide Personalized Glycemic Profiles as Part of a Pilot Worksite Health Screening.
Crawford M, Johnson M, Klein IJ, Hames KC, et al · · 2021 · cited 1× · PMID 33095028 · DOI 10.1177/1932296820966630
Verify or expand the search:
- PubMed search for NCT04529824
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other DexCom, Inc. trials
Trials by the same sponsor.
- NCT06483945 — Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry) · recruiting
- NCT05746286 — Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia · NA · completed
- NCT04905628 — Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus · unknown
- NCT04794478 — Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System · NA · completed
- NCT04840446 — Evaluation of Modified Adhesives With Dexcom G6 Sensor · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04529824 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by DexCom, Inc.
- Last refreshed: 15 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04529824.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing